RE: Share Price Decline26 Jun 2023 20:15
Crumbs
Well, I think you'll find Our very own Mr Diggle has expressed concern at the lack of commercialisation of Scancell's assets. He also spoke of the derisory SP level.
That's someone who is a senior investor here expressing the view that Scancell needs to get its finger out in order to raise some capital to meet its looming commitments.
However you might interpret that point differently.
That's a market I believe.
I don't think I've let myself down at all.
I've spent quite a few years now being told that I've got it wrong, but so far my portfolio disagrees with that.
I've just fitted Vulpes into my comments. Redmile fit into it neatly because their massive CLN holding was adjusted by having the maturity date shifted by two years. That was a pretty good indicator that "Jam tomorrow" was being kicked down the road, and so it has been. Scancell will have to cover that liability which unless they commercialise will be another short/medium term worry.
So you see (much even as you have suggested) the window for breathing financially easily will slam shut very soon, and with the global financial climate (even for Bios) indicating a bit of a chill times are not easy for a bio with a cash requirement which is heading up fast; hence my comment for some form of cash injection by way of asset disposal maybe.
That said, if no assets can be monetised what's the next port of call for cash?
I won't say it because we all know what that is.... so how do we get the SP North so that the diluting effect of something cobbled together down at this level (What was the SP at the second capital raise in 2020 (nearly THREE years ago) , my, how time flies!
So be very careful in assuming that the SP will now easily rush north on average Trial results.
Maybe they will be better than expected, I hope so, but don't assume anything when the Company could look vulnerable.
People have been making a big thing of being LTHs. Yep, I understand that, but Vulpes and RM have to show a turn on their capital, Not for them BUYING and BUYING and BUYING using the lowering average as an excuse. For them the non movement of the SP for three years is not good news. Yes, they know how the industry works, but they still have to appease their investors. Look at the frustration shown by Calculus, one of Scancell's greatest friends. They had to move some stock.
So fine, I long for the panacea of great Data, but great data requires monetisation, you can't rest on your laurels discussing the science forever. The BOD has to deliver,,,, and soon!
AIMO